AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01481948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food, Fun, & Fitness Internet Program for Girls
Description: This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
Study NCT02555228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
Study NCT02975882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given PO
Study NCT02975882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02975882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02975882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Albumin-bound Nanoparticles
Description: Given IV
Study NCT02975882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT04574076 — intervention group
Intervention type: DRUG
Intervention: Turoctocog alfa pegol (N8-GP)
Description: Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study NCT02555228 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 5mls of water is given at least 30 minutes before the gastroscopy.
Study NCT03981250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week home-based resistance exercise programme
Description: Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
Study NCT04335123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
Study NCT01160692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/Multimineral/Ginkgo (BAY 81-2775)
Description: Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
Study NCT01160692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral intake of matching placebo tablets for 3 months
Study NCT03105908 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet delivered Acceptance and Commitment therapy
Description: The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
Study NCT03105908 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list control condition
Description: After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
Study NCT03538730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Reframing
Description: The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
Study NCT04603872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/BCMA Targeted CAR T-cells and dasatinib
Description: Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
Study NCT04603872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/BCMA Targeted CAR T-cells
Description: Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
Study NCT02175433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion
Study NCT01047384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture-moxibustion therapy
Study NCT01047384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular therapy
Study NCT03225105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3541
Description: Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).
Study NCT03225105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy (RT)
Description: Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).
Study NCT04316871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 mg of Morphine Sulfate
Description: 1.5 mg of Morphine Sulphate will be given epidurally.
Study NCT04316871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be given epidurally.
Study NCT02515773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin - to achieves maximum insulin-sensitizing effects
Study NCT02515773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle intervention (LIFE)
Description: Healthy Life style intervention
Study NCT01764204 — intervention group
Intervention type: DRUG
Intervention: Qingkailing Injection
Description: Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
Study NCT01218620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Given PO
Study NCT01218620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Given PO
Study NCT01218620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Given PO
Study NCT01218620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01218620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04526678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplement (27mg)
Description: The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
Study NCT01348542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50 mg once a day, for 3 months
Study NCT01348542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
Study NCT00747747 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: 3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
Study NCT00747747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinuclean DM Spray
Description: 3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
Study NCT04177810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
Study NCT04177810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
Study NCT01563432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feburic®
Description: 80 mg\*1 tablet
Study NCT01563432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMX-67
Description: 40 mg\*2 tablets
Study NCT03031457 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Duplex ultrasound of lower extremity venous system
Study NCT04314427 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Study NCT04314427 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Study NCT01507831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Study NCT01507831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Study NCT01507831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT01507831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT03729752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [89]Zr-DFO-VRC-HIVMAB060-00-AB
Description: Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
Study NCT03729752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89]Zr-DFO-VRC-HIVMAB060-00-AB
Description: Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
Study NCT01851590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Lacquer
Description: 30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
Study NCT01851590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amorolfine
Description: 5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
Study NCT01851590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: 250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
Study NCT00977964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process A
Description: ad lib for 1-8 days of age until 28 days of age
Study NCT00977964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process B
Description: ad lib from 1-8 days of age until 28 days of age
Study NCT00977964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process C
Description: ad lib from 1-8 days of age to 28 days of age
Study NCT00977964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process D
Description: ad lib from 1-8 days of age until 28 days of age
Study NCT00977964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process E
Description: ad lib from 1-8 days of age until 28 days of age
Study NCT00977964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process F
Description: ad lib from 1-8 days of age until 28 days of age
Study NCT00623623 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary PCI
Description: Standard primary PCI
Study NCT00623623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Adjunctive treatment
Study NCT00623623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheterisation
Description: Routine or rescue coronary intervention
Study NCT00623623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase
Description: Single, weight-adjusted i.v. bolus of tenecteplase
Study NCT00623623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Adjunctive treatment
Study NCT06371716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA
Study NCT06371716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
Study NCT06371716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-single dose
Description: Tramadol single oral dose (first 8 hours)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-single dose
Description: Dexketoprofen single oral dose (first 8 hours)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-single dose
Description: Dexketoprofen/Tramadol oral single dose (first 8 hours)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Study NCT01902134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Study NCT01122472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Daily for 3 weeks every 4 weeks for 24 months
Study NCT01122472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 3 weeks every 4 weeks for 24 months
Study NCT02868281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT guided Routine Treatment
Description: The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
Study NCT02868281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Treatment
Description: Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
Study NCT03374137 — intervention group
Intervention type: BIOLOGICAL
Intervention: obinutuzumab
Description: Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
Study NCT04317833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS17
Description: SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
Study NCT04317833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT03096574 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
Study NCT01814137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
Study NCT01814137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
Study NCT01814137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
Study NCT01814137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
Study NCT01613131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
Study NCT01613131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirena
Description: Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
Study NCT01613131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Topical, .06%, Applied once daily for 50 days.
Study NCT01613131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Topical Gel, Applied once daily for 50 days, Placebo comparator.
Study NCT00367666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)
Study NCT04042974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study NCT04042974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study NCT04917900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
Description: Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.